NovoCure (NVCR) Research & Development (2014 - 2026)

NovoCure has disclosed Research & Development across 13 years of filings, most recently posting $58.3 million for Q1 2026.

• Research & Development for Q1 2026 came in at $58.3 million, up 8.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $229.1 million (up 8.16% YoY), and the FY2025 annual result was $224.5 million, up 7.11% from the prior year.
• Research & Development came in at $58.3 million for Q1 2026 at NovoCure, down from $60.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $60.9 million in Q4 2025 to a low of $42.2 million in Q1 2022.
• The 5-year median for Research & Development is $54.3 million (2023), against an average of $54.2 million.
• Across the five-year window, Research & Development surged 41.36% in 2023 and retreated 13.58% in 2024, its largest moves.
• NovoCure's Research & Development stood at $54.8 million in 2022, then dropped by 0.93% to $54.3 million in 2023, then retreated by 5.7% to $51.2 million in 2024, then increased by 18.93% to $60.9 million in 2025, then slipped by 4.22% to $58.3 million in 2026.
• The last three Research & Development figures came in at $58.3 million (Q1 2026), $60.9 million (Q4 2025), and $54.0 million (Q3 2025), per Business Quant data.